Mechanical Study of Jian-Gan-Xiao-Zhi Decoction on Nonalcoholic Fatty Liver Disease Based on Integrated Network Pharmacology and Untargeted Metabolomics

Figure 3

Experimental validation of network pharmacology analysis (a) JGXZ treatment increased the SOD and GSH-Px activities, and reduced the MDA level in the liver tissue homogenate. (b) JGXZ downregulated the protein expressions of Fas and Cytochrome C expression in the liver tissue. (c) JGXZ treatment decreased the levels of pro-inflammatory cytokines in the liver tissues. (d) JGXZ downregulated the protein expressions of NF-κB p65 phosphorylation, JNK1/2, and C-JUN in the liver tissue. (e) JGXZ downregulated the protein expressions of SERBP1 and Leptin in the liver tissue. (f) JGXZ treatment reduced the FINS level and HOMA-IR in NAFLD model rats. (g) JGXZ downregulated the protein expressions of GSK3β and CYP2E1 in the liver tissue.

(a)

(b)

(c)

(d)

(e)

(f)

(g)